Crohns Disease

Read Full Post »

According to a new study from the Mayo Clinic the use of infliximab (IFX) plus azathioprine (AZA) and infliximab monotherapy increase the likelihood of patients achieving long-term steroid-free clinical remission in patients with moderate to severe Crohns disease.

Read Full Post »

patients hospitalized with inflammatory bowel disease were 39% more likely to become infected with methicillin-resistant Staphylococcus aureus (MRSA) than those admitted with other gastrointestinal conditions

Read Full Post »

New studies show that patients with moderate to severe Crohn’s disease can maintain remission through three years of therapy with adalimumab (HUMIRA®).

Read Full Post »

A US company called WellApps have launched an iPhone application to help people with (IBD) Crohn’s and Ulcerative Colitis

Read Full Post »

New research investigating the impact that patients’ attitudes to maintenance therapy (MT) has on nonadherence in Inflammatory Bowel Disease (IBD) has been published today in Inflammatory Bowel Diseases

Read Full Post »

The first Service Standards for the care of patients with inflammatory bowel disease (IBD) was launched yesterday at The House of Lords. This was marked by Lord Newton of Braintree as “a major development for people with Colitis and Crohn’s disease”. The simple truth is that patients in the UK, unless they are willing to [...]

Read Full Post »

The term Inflammatory Bowel Disease (IBD) generally refers to both Crohn’s Disease (CD) and Ulcerative Colitis (UC), which, as the name suggests are both chronic diseases involving inflammation of the gastrointestinal tract.

Read Full Post »